- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02922946
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
A 2-Stage, Open-Label, Randomized, Single-Dose, Crossover Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a 2-stage food effect (timing of the meal) study. A total of 48 subjects will be dosed if Stage 2 is conducted.
Stage 1 will be conducted as an open-label, randomized, 2-way crossover study. On Day 1 of each period, subjects will receive a single, oral dose of entinostat under fasting or fed conditions.
If preliminary results in Stage 1 indicate that the timing of a meal exhibits significant effect on the bioavailability of entinostat, then Stage 2 will be conducted which will investigate the effect of a meal either before or after dosing of entinostat on entinostat PK.
Stage 2 will be conducted as an open-label, randomized, 3-way crossover study. On Day 1 of each period, subjects will receive a single, oral dose of entinostat under fasting or fed conditions.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults 19-55 years of age at screening.
- Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to first dose and throughout the study.
- Body mass index of ≥ 18.5 at screening.
- Medically healthy with no significant medical history, physical examination, laboratory values, vital signs, or ECGs. Liver function tests and serum bilirubin must be ≤ the upper limit of normal. Platelets, hemoglobin, and hematocrit must be > the lower limit of normal at screening.
- Females of non-childbearing potential must have undergone sterilization procedures as noted in protocol at least 6 months prior to dose.
- Non-vasectomized male subjects must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond dose of study drug.
- Male subjects must agree not to donate sperm from the first dose until 90 days beyond dose of study drug.
- Understands the study procedures in the informed consent form and be willing and able to comply with the protocol.
Exclusion Criteria:
- Mentally or legally incapacitated or has significant emotional problems at screening or expected during the conduct of the study.
- History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
- History of illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study in the opinion of the PI or designee.
- History of presence of alcoholism or drug abuse within the past 2 years prior to dose.
- History or presence of clinically significant cancer, cardiovascular disorders, acute or chronic gastrointestinal conditions in the opinion of the PI.
- Females of childbearing potential.
- Females with a positive pregnancy test or lactating.
- Positive urine drug or alcohol results are screening or each check-in.
- Positive urine cotinine at screening.
- Positive results are screening for HIV, hepatitis B surface antigen, or hepatitis C virus
- Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
- Seated heart rate lower than 40 bpm or higher than 99 bpm at screening.
- QTcB interval (correction value of the interval between the Q and T waves on the ECG tracing using the Bazett Correction Formula) > 460 msec for males or > 480 msec for females or has ECG findings deemed abnormal by the PI or designee.
- Estimated creatinine clearance < 90 mL/min at screening.
- Unable to refrain from or anticipates the use of any prescription or non-prescription medications and any drugs known to be significant inhibitors or CYP (Cytochromes 450) enzymes and/or P-gp.
- Has been on a diet incompatible with the on-study diet within 28 days prior to dose and throughout the study in the opinion of the PI or designee.
- Is lactose intolerant.
- Donation of blood or significant blood loss within 56 days prior to dose.
- Plasma donation within 7 days prior to dose.
- Participation in another clinical study 28 days prior to dose.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Entinostat 5mg in 2-Way Crossover
Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast. Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast. |
HDAC (histone deacetylase) inhibitor
Other Names:
|
Experimental: Entinostat 5mg in 3-Way Crossover
Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast. Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal. Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast. |
HDAC (histone deacetylase) inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in physical exam
Time Frame: Baseline through Day 1
|
Baseline through Day 1
|
Changes from baseline in vital signs
Time Frame: Baseline through Day 22
|
Baseline through Day 22
|
Changes from baseline in clinical laboratory tests
Time Frame: Baseline through Day 1
|
Baseline through Day 1
|
AUC0-t (area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) for entinostat under fed and fasting conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
AUC0-inf (area under the concentration-time curve, from time 0 extrapolated to infinity) for entinostat under fed and fasting conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
Cmax (maximum observed concentration) of entinostat under fed and fasting conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
AUC%extrap (percent of AUC0-inf extrapolated) of entinostat under fed and fasting conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
Tmax (time to reach maximum observed concentration) of entinostat under fed and fasted conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
Kel (apparent terminal elimination rate constant) of entinostat under fed and fasted conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
T1/2 (apparent terminal elimination half-life) of entinostat under fed and fasted conditions
Time Frame: Pre-dose through Day 22
|
Pre-dose through Day 22
|
Changes from baseline in ECG results
Time Frame: Baseline through Day 22
|
Baseline through Day 22
|
Changes from baseline in adverse events
Time Frame: Baseline through 14 days after last sample collection
|
Baseline through 14 days after last sample collection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNDX-275-0180
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
-
Yuhan CorporationNot yet recruitingHealthy Volunteers
Clinical Trials on Entinostat
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative DiseasesUnited States
-
Hetty CarrawayActive, not recruitingAcute Myeloid LeukemiaUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Completed
-
University Hospital HeidelbergGerman Cancer Research CenterRecruitingSolid Tumor | CNS TumorFrance, Germany, Australia, Austria, Sweden, Netherlands, Switzerland
-
Abramson Cancer Center at Penn MedicineCompletedColorectal CancerUnited States
-
Syndax PharmaceuticalsPfizer; Merck KGaA, Darmstadt, GermanyCompletedStudy of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited States
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCCompletedMelanoma | Non-Small Cell Lung Cancer | Mismatch Repair-Proficient Colorectal CancerUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaSyndax PharmaceuticalsWithdrawn